Johnson & Johnson’s experimental COVID-19 vaccine candidate has reportedly developed a strong immunity against the novel coronavirus.
The single dose of the COVID-19 vaccine developed by the American multinational corporation has been well responded in the early-to-mid stages of the clinical trial.
The early result shows that the vaccine named Ad26.COV2.S was equally well-tolerated at two different doses. However, it is unclear whether J&J’s cure will protect the elderly, as same as the young.
Based on the current findings, the pharma firm entered a final 60,000-person trial on Wednesday, which could pave the way for a regulatory approval submission.
“It expects results from the so-called Phase 3 trial by the end of the year or early next year”, the company said.
The findings, reported on the medRxiv medical site, have not been peer-reviewed.
29 days after vaccination, 98 percent of participants with data available for interim review had neutralizing antibodies that protect cells against pathogens, said researchers including J&J Unit Jansen Pharmaceuticals.
When the study is completed more details are expected to be available on the safety and efficiency of the vaccine.
According to the reports, the results now justify why more studies are needed for serious adverse outcomes, said professor Barry Bloom at the Harvard TH Chan School of Public Health.
“Overall, the vaccine is doing what you would expect it to do if you were to move it to Phase 3 trials,” Prof. Bloom said.